Skip to main content


We're creating a new version of this page. See preview

  • Research article
  • Open Access
  • Open Peer Review

Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE)

  • 1,
  • 2, 3, 4,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2, 3, 4,
  • 2, 3, 4,
  • 1,
  • 1Email author and
Contributed equally
BMC NephrologyBMC series – open, inclusive and trusted201718:311

  • Received: 29 May 2017
  • Accepted: 22 September 2017
  • Published:
Open Peer Review reports



This study aimed to compare clinical features and health-related quality of life (HRQoL) in the Chinese chronic kidney disease (CKD) 3 population and determined the necessity of the subdivision of CKD3 in Chinese patients with CKD.


Participants with stage 3 CKD (18–74 years of age) were recruited at 39 clinical centers located at 28 cities in 22 provinces of China. The sociodemographic status, medical history, anthropometric measurements, and lifestyle behaviors were documented at entry, and blood and urine samples were collected. The estimated glomerular filtration rate was calculated using the CKD-EPI creatinine equation. The HRQoL was evaluated using the kidney disease quality-of-life instrument. A linear regression model was used to estimate the association between HRQoL and CKD stages (G3b vs G3a).


The levels of intact parathyroid hormone, systolic blood pressure, uric acid, and high-density lipoprotein cholesterol were statistically significantly higher, whereas the levels of serum bicarbonate and hemoglobin were statistically significantly lower in the G3b group compared with the G3a group. Compared with CKD G3a group, the proportions of subjects with hyperuricemia and anemia were significantly higher in CKD G3b group (61.4% vs. 52.0% and 26.4% vs. 17.9%, respectively, P< 0.01). The HRQoL scores in “physical functioning (PCS)”, “symptoms and problems”, “effects of the kidney disease” and “burden of the kidney disease” were statistically significantly lower in the CKD G3b group compared with the CKD G3a group (90.88 ± 11.05 vs. 89.30 ± 11.52, 88.29 ± 11.94 vs. 86.49 ± 13.45, 55.86 ± 26.40 vs. 52.10 ± 27.64, 46.56 ± 8.16 vs. 44.51 ± 9.22, respectively, P< 0.01). Further, CKD G3b was associated with a lower score of physical functioning compared with G3a (regression coefficient =−1.12 [95%CI: −2.23, −0.16]).


The preliminary results of this study suggested that modest differences existed in many important clinical features and KDQoL between patients with G3a and G3b CKD in a Chinese population. Also, a significant association between CKD3 subdivision of the disease and PCS was detected. Although further work is needed, we can speculate based on these results the CKD3 subdivision may be clinically meaningful for Chinese patients with CKD.


  • Chronic kidney disease stage 3
  • Clinical features
  • Health-related quality of life
  • Subdivision


Chronic kidney disease (CKD) is a dangerous, life-threatening illness defined by declining renal function that gradually progresses to end-stage renal disease (ESRD) [1]. Globally, approximately 200 million patients with CKD have been reported [2]. CKD has also become a leading health problem in China with an estimated 119.5 million patients suffering from the disease as inferred by a recent countrywide survey that demonstrated the 10.8% overall prevalence [3]. This means that more than 50% of patients with CKD in the planet live in China. With a booming economy and aging population, the prevalence is projected to grow continuingly in the near future. CKD is a significant financial burden on global health care systems [4, 5]. The cost of dialysis treatment alone for one patient would be around $14,300 per year, whereas the per capita disposable income is $1210 in urban areas and $375 in rural areas in China [6]. Therefore, the rapidly increasing CKD epidemics cause substantial socioeconomic and public health burden to the Chinese society. Understanding the CKD epidemiology is crucial to control the number of CKD cases in China.

In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) recommended reclassifying CKD [7], which included a two-dimensional staging of CKD according to the urine albumin-to-creatinine ratio. Furthermore, the classification split CKD stage 3 into two subgroups by applying a cutoff point of eGFR (45 mL/min 1.73 m2). Hence, subjects with CKD G3a were considered low-risk compared with patients with CKD G3b. This new classification was based on a meta-analysis performed in 45 cohorts involving over 1.5 million participants mainly from developed countries [7]. However, the CKD population in China, the largest developing country, is quite different from that in developed countries. The analysis showed that the stages 3 and 4 CKD prevalence was lower compared with that in developed countries. For example, the prevalence of stage 3 CKD was 1.6% in China compared with 7.7% in the USA and 4.2% in Norway [3]. The rise in obesity and type 2 diabetes mellitus, along with a growing aging population, has exacerbated the financial and medical burden of CKD in China [8, 9]. Due to a lack of resources, however, fewer patients in China receive dialysis compared with those in Western countries. It is still unknown whether this revised classification is suitable for Chinese patients with CKD.

Patients with CKD experience limited health-related quality of life (HRQoL). While the relationship between HRQoL and increased mortality in patients with ESRD is well-established, little is known about the association between early stage of CKD and HRQoL in China. The present study aims to compare clinical features and CKD-related quality of life in the Chinese CKD3 population and determine the necessity of the subdivision of CKD3 in Chinese patients with CKD.


Study population and methods

The design and methods of the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE) study were published in detail previously [10, 11]. The study was a prospective project which included 39 clinical centers located in 28 cities in 22 provinces of China. All these clinical centers were renal departments from different hospitals. Altogether, 3499 Chinese patients with pre-stage 5 CKD enrolled in the study; 2870 of them completed the required examinations in their entirety. Six hundred twenty nine were excluded from the study due to missing values in key demographic variables or serum creatinine. Of the 2870, a total of 1277 patients with CKD 3 were included in the study analysis.

The baseline data included: detailed demographics; financial, sociological and health care related information; medical and family history including previously taken medications; and questionnaires related to quality of life, health behaviors, and physical activity. Height, weight, waist and hip width, resting blood pressure, and heart rate were collected. Laboratory parameters including complete blood count, serum uric acid, serum creatinine, serum cholesterol, serum calcium and phosphate, fasting blood glucose, high-sensitivity C-reactive protein (Hs-CRP), intact parathyroid hormone (iPTH), urine dipstick, albumin-to-creatinine ratio (ACR), 24-h urine protein, electrolytes, 12-lead surface electrocardiography, echocardiogram and lateral abdominal radiograph were collected for each participant.

The eGFR was determined with the chronic kidney disease epidemiology collaboration equation (CKD-EPI) for Chinese patients with CKD. CKD stage was determined using eGFR and ACR levels. The eGFR stage was graded as follows: G3a, eGFR: 45–59 mL/(min 1.73 m2) and G3b, eGFR: 30–44 mL/(min 1.73 m2). The albumin-urine stage was categorized according to an analysis of a spot urine sample: A1 (normoalbuminuria), ACR <30 mg/g creatinine; A2 (microalbuminuria), 30 ≤ ACR < 300 mg/g creatinine; or A3 (macroalbuminuria), ACR ≥300 mg/g creatinine. The A1 stage was sectioned into groups by ACR as follows: A1a, ACR <10 mg/g creatinine and A1b, 10 ≤ ACR < 30 mg/g creatinine.

CKD-related complications that were assessed included hypertension, diabetes, hyperlipidemia, hyperuricemia, anemia, metabolic acidosis, CKD-mineral and bone disorders (CKD-MBD), and cardiovascular disease (CVD). Baseline hypertension was described as a systolic blood pressure > 140 mmHg; a diastolic blood pressure > 90 mmHg (at least three high readings taken within a week of each other); use of antihypertensive medications; or any self-reported history of hypertension. Patients were considered to have diabetes mellitus if they had a fasting glucose ≥7.0 mmol/L; an HbA1c ≥ 6.5%; took insulin or other anti-diabetic medications; or reported a history of diabetes. Hyperlipidemia was defined as a serum concentration with a total cholesterol level ≥ 5.7 mmol/L and an LDL-cholesterol level ≥ 3.6 mmol/L. Hyperuricemia was defined as a serum concentration of uric acid ≥420 μmol/L for men and ≥360 μmol/L for women. Anemia was determined in patients with a hemoglobin level < 120 g/L for men and <110 g/L for women. Metabolic acidosis was identified as a plasma bicarbonate (HCO3) concentration < 22 mmol/L. CKD-MBD was defined as a triad of interrelated abnormalities of serum biochemistry (serum phosphate levels >1.49 mmol/L or <0.87 mmol/L, serum calcium levels >2.37 mmol/L or <2.1 mmol/L, and iPTH >70 pg/mL or <35 pg/mL), bone, and vasculature (plain lateral abdominal x-ray film showed abdominal aortic calcification) associated with CKD. Cardiovascular disease (CVD) was defined as the past occurrence of a myocardial infarction, admittance into a hospital for congestive heart failure, or severe cardiac arrhythmia incidents (resuscitated cardiac arrest, ventricular fibrillation, sustained ventricular tachycardia, paroxysmal ventricular tachycardia, atrial fibrillation or flutter, severe bradycardia, or heart block). Echocardiography showed left ventricular end-systolic diameter (LVESD) >50 mm and/or ejection fraction (EF) <50%.

The Mandarin Chinese version of kidney disease quality of life (KDQoL)-36 instrument, an globally accepted tool, was used for evaluating HRQoL of patients with CKD [12]. The Mandarin Chinese KDQoL-36 was a short, accurate and consistent tool used to determine the quality of life of patients with CKD in China [13]. The disease-related section consisted of 24 items which made up three scales: Symptoms and Problems (12 items), Burden of Kidney Disease (4 items), and Effects of Kidney Disease (8 items). The generic core was the 12-item Short-Form Health Survey (SF-12). The results of the SF-12 instrument were summarized into the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score. The raw scores were transformed linearly into a range of 0–100 with higher scores representing greater HRQoL [14] (

Statistical methods

Continuous variables were presented as means with standard deviations (SDs) except for serum total cholesterol, duration of CKD, ACR, and Hs-CRP. There were displayed as median (interquartile range) due to high skewness. Categorical variables were presented as counts and proportions. The statistical significance of differences in clinical characteristics was examined using Student t test (continuous variables), Wilcoxon signed-rank test (variables with high skewness), and chi-square test (categorical variables). The trend analysis in the proportions among ordinal multiple categorical variables was examined using the Mantel–Haenszel test.

The associations between CKD-related quality of life and CKD stages (G3b vs G3a) were analyzed using a linear regression model. The variables included in the regression model were gender (male vs. female), age (continuous, change by 10 years), high school education (yes vs. no), current smoking (yes vs. no), CVD (yes vs. no), diabetes mellitus (yes vs. no), hyperuricemia (yes vs. no), high blood pressure (yes vs. no), albuminuria (A2 vs. A1 and A3 vs. A1), anemia (yes vs. no), CKD-MBD (yes vs. no), hyperlipidemia (yes vs. no), and metabolic acidosis (yes vs. no). Multiple imputations were performed to handle missing data to reduce the loss of information and account for the uncertainty of missing data in the regression analysis. The regression method was used to impute missing values in a normally distributed continuous variable, predictive mean matching method was used in a skewed distributed continuous variable, and logistic regression was used in a categorical variable with binary or ordinal responses. Twenty-five imputed data sets were generated with the number of iterations of 20. Each imputed dataset was analyzed separately, and then pooled results were obtained. The total percentage of individuals imputed was 32% (407/1277).

All P values were two sided. A P value <0.05 was deemed to be statistically significant. All analyses were performed using the software program the Statistical Analysis System (SAS) (version 9.4, SAS Institute, CA, USA).


Patient characteristics and HRQoL scores

A population of 1277 patients with CKD3 was recruited for the study. The mean age of patients with CKD3 was 51.68 ± 12.81 years, and 60.9% (813) were male. Demographic and laboratory parameters are presented in Table 1, with the patients divided into two groups according to eGFR (mL/(min 1.73 m2)): CKD G3a, with eGFR range 45–59 (n = 499, 39.1%), and CKD G3b, with eGFR range 30–44 (n = 778, 60.9%). As shown in Table 1, patients in the CKD G3a group had a mean age of 49.84 ± 12.76 years with 40.8% of men, whereas patients in the CKD G3b group had a mean age of 52.86 ± 12.71 years with 71.1% of men. The high school education level was lower in the CKD G3b group compared with the CKD G3a group (51.8% vs 64.0%, P < 0.01). The levels of iPTH, systolic blood pressure, uric acid, and high-density lipoprotein (HDL) cholesterol were statistically significantly higher in the G3b group compared with the G3a group (P < 0.05). The levels of serum bicarbonate and hemoglobin were statistically significantly lower in the G3b group compared with the G3a group (P < 0.05). The proportions of subjects with hyperuricemia and anemia were statistically significantly higher in the CKD G3b group compared with the CKD G3a group (61.4% vs 52.0%, 26.4% vs 17.9%, respectively, P < 0.01). The age- and gender-adjusted prevalence of CKD-related complications in CKD G3b based on the age and gender distribution of CKD G3a was similar to the unadjusted result (Additional file 1: Table S1). The HRQoL scores in “physical functioning,” “symptoms and problems,” “effects of the kidney disease,” and “burden of the kidney disease” were statistically significantly lower in the CKD G3b group compared with the CKD G3a group (P < 0.05), but the difference was modest.
Table 1

Demographic, laboratory parameters and KDQoL subscales of patients with CKD 3 from C-STRIDE Study


CKD G3a (n = 499)

CKD G3b (n = 778)

Missing value


Age (years)

49.84 ± 12.76

52.86 ± 12.71




355 (71.1%)

458 (58.8%)



Duration of CKD (years)

1 (0,4)

1 (0,4)



Current smoking

199 (40.9%)

313 (41.9%)



Drinkers (≥1 times per day)

15 (3.1%)

23 (3.1%)



High school education (%)

315 (64.0%)

398 (51.8%)



Body mass index (kg/m2)

24.71 ± 3.37

24.78 ± 4.70



Systolic blood pressure (mmHg)

129.54 ± 16.67

132.01 ± 17.16



Diastolic blood pressure (mmHg)

82.29 ± 15.56

81.65 ± 10.74




400 (80.2%)

631 (81.1%)



Serum total cholesterol (mmol/L)

4.89 (4.00,5.97)

4.68 (3.86,5.79)



Serum LDL cholesterol (mmol/L)

2.67 ± 0.94

2.66 ± 1.00



Serum HDL cholesterol (mmol/L)

1.07 ± 0.31

1.13 ± 0.41




155 (33.8%)

214 (29.2%)



Serum creatinine (μmol/L)

129.50 ± 18.84

163.27 ± 27.49



eGFR (mL/min/1.73 m2)

51.61 ± 4.24

37.13 ± 4.33



Fasting Blood glucose (mmol/L)

5.28 ± 1.73

5.41 ± 1.86



Diabetes mellitus

130 (26.1%)

216 (27.8%)



Cardiovascular disease

128 (25.9%)

218 (28.5%)



Uric acid (μmol/L)

402.46 ± 105.51

426.14 ± 111.37




256 (52.0%)

471 (61.4%)




39.81 ± 6.96

39.56 ± 6.60



ACR (mg/g creatinine)

315.37 (63.67,724.88)

340.19 (74.78,860.03)




230 (53.4%)

332 (50.2%)




134.17 ± 21.68

127.56 ± 46.83




83 (17.9%)

185 (26.4%)



Serum Bicarbonate

26.49 ± 4.20

25.46 ± 3.83



Metabolic Acidosis

109 (21.8%)

180 (23.1%)



Serum calcium

2.24 ± 0.22

2.25 ± 0.22



Serum phosphorus

1.17 ± 0.40

1.18 ± 0.25



Serum iPTH

47.95 ± 28.94

59.15 ± 37.74




398 (79.8%)

636 (81.8%)




1.5 (0.66,3.33)

1.4 (0.59,3.72)



Symptoms and Problems (S)

90.88 ± 11.05

89.30 ± 11.52



Effects of the Kidney disease (E)

88.29 ± 11.94

86.49 ± 13.45



Burden of the Kidney disease (B)

55.86 ± 26.40

52.10 ± 27.64



SF-12 Physical Functioning (PCS)

46.56 ± 8.16

44.51 ± 9.22



SF-12 Mental Functioning (MCS)

51.18 ± 8.38

50.2 ± 9.20



Continuous variables are presented as mean ± SD, or median with interquartile ranges. Categorical data are presented as numbers (n) of patients

Abbreviations: CKD Chronic kidney disease, LDL Low-density lipoprotein, HDL High-density lipoprotein, eGFR estimated glomerular filtration rate, ACR Albumin to creatinine ratio, CKD-MBD CKD-mineral and bone disorders, Hs-CRP high-sensitivity C-reactive protein

Proportions of CKD-related complications according to a two-dimensional staging of CKD

Patients with CKD G3a and G3b were classified according to the levels of ACR, and the proportions of CKD-related complications, including hypertension, hyperlipidemia, hyperuricemia, anemia, metabolic acidosis, CKD-MBD, and CVD, were compared. A general trend of higher prevalence of hyperuricemia or anemia through increased ACR levels was observed when the G3b group compared with the G3a group (Table 2, P for trend <0.01).
Table 2

The percentages of CKD related complications in the groups staged by eGFR and ACR levels


CKD G3a (n = 417)

P for trend (G3a)

CKD G3b (n = 685)

P for trend (G3b)


A1a n = 39

A1b n = 45

A2 n = 118

A3 n = 215

A1a n = 43

A1b n = 56

A2 n = 226

A3 n = 360

P for trend (total)


32 (82.1%)

36 (80.0%)

101 (85.6%)

167 (77.7%)


35 (81.4%)

43 (76.8%)

187 (82.7%)

293 (81.4%)




11 (28.2%)

15 (33.3%)

34 (28.8%)

77 (35.8%)


6 (14.0%)

11 (19.6%)

51 (22.6%)

127 (35.3%)




21 (53.9%)

17 (37.8%)

61 (51.7%)

117 (54.4%)


19 (44.2%)

34 (60.7%)

151 (66.8%)

214 (59.4%)




7 (18.0%)

8 (17.8%)

17 (14.4%)

43 (20.0%)


12 (27.9%)

9 (16.1%)

40 (17.7%)

104 (28.9%)



Metabolic Acidosis

3 (7.7%)

9 (20.0%)

22 (18.6%)

38 (17.7%)


9 (20.9%)

15 (26.8%)

50 (22.1%)

64 (17.8%)




30 (76.9%)

33 (73.3%)

95 (80.5%)

168 (78.1%)


31 (72.1%)

49 (87.5%)

181 (80.1%)

291 (80.8%)




10 (25.6%)

18 (40.0%)

21 (17.8%)

63 (29.3%)


11 (25.6%)

18 (32.1%)

71 (31.4%)

98 (27.2%)



Quality of Life

40.15 ± 18.69

38.41 ± 17.76

43.87 ± 18.52

42.18 ± 19.16


37.16 ± 16.27

42.68 ± 17.89

39.54 ± 19.42

38.98 ± 20.71



Continuous variables are presented as mean ± SD, or median with interquartile ranges. Categorical data are presented as numbers (n) of patients

Abbreviations: CKD-MBD CKD-mineral and bone disorders, CVD Cardiovascular disease

Multiple linear regression

A multiple linear regression analysis was conducted to estimate the relationship between HRQoL and CKD stages (G3b vs G3a). As shown in Table 3, the CKD stage (G3b vs G3a) was independently associated with SF-12 PCS. CKD G3b was associated with a lower score of physical functioning [regression coefficient = −1.12; 95% confidence interval (CI): −2.23 to −0.16] compared with G3a.
Table 3

The linear association between chronic kidney disease G3a/G3b and KDQoL subscales

Risk factor

Regression coefficient (95% confidence interval)a


Symptoms and Problems (S)

−0.91 (−2.26,0.43)


Effects of the Kidney Disease (E)

−1.38 (−2.94,0.17)


Burden of the Kidney Disease (B)

−3.00 (−6.25,0.26)


SF-12 Physical Functioning (PCS)

−1.12 (−2.23,-0.16)


SF-12 Mental Functioning (MCS)

−1.00 (−2.08,0.06)


aAdjusted for age, gender, education level, current smoking, hypertension, diabetes, cardiovascular disease, diabetes mellitus, hyperuricemia, high blood pressure, albuminuria, anemia, CKD-mineral and bone disorders, hyperlipidemia and metabolic acidosis


The present study investigated clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b from the C-STRIDE Study in China. The findings could be summarized as follows: Significant differences were observed in many important clinical features, including the levels of iPTH, systolic blood pressure, uric acid, HDL cholesterol, serum bicarbonate, and hemoglobin, and the prevalence of hyperuricemia and anemia between the CKD G3b and CKD G3b groups. The HRQoL scores were statistically significantly higher in patients with CKD G3b group compared with scores of patients with CKD G3a. CKD G3b was associated with a lower score of SF12 physical functioning.

Stage 3 CKD is the first stage that can be identified from the serum creatinine test alone and accounts for the vast majority of people now being detected and labeled with CKD on general practice disease registers [15]. In a national study of 47,204 Chinese adults, the adjusted prevalence of stage 3 CKD was 1.6% (95% CI: 1.4–1.8) compared with 0.1% (95% CI 0.06–0.2) in stage 4 and 0.03% (95% CI 0.01–0.05) in stage 5 [3]. Consistently, patients with stage 3 CKD outnumber those with stage 4 almost 20-fold [16]. The clinical implications of patients with stage 3 are less clear compared with the patients with higher CKD stages, whose clinical features and outcomes of CKD are well understood. Many scientists recommend subdividing stage 3 into stages G3a (45–59 mL/min) and G3b (30–44 mL/min), since these subgroups may associate with unique clinical patterns [17, 18]. In a meta-analysis conducted by KDIGO in 2009, a steep rise in risk of mortality and kidney outcomes with lower eGFR in the range of 30–59 mL/(min 1.73 m2) was observed, which was consistent with the proposal to divide stage 3 into two stages [7].

The results of this study confirmed different clinical features and HRQoL between patients with CKD G3a and G3b in China. Consistently with our findings, Ito et al., in a cross-sectional study of 2088 Japanese patients with type 2 diabetes mellitus, observed that the percentage of patients with diabetic retinopathy, neuropathy and other complications was statistically higher in patients with CKD G3b than in patients with CKD G3a [19]. A group of 390 Chinese patients with immunoglobulin A nephropathy (IgAN) showed that grouping IgAN patients with CKD stage 3 by G3a and G3b was useful in evaluating risk of disease progression and assessing prognosis of patients [20].

Previous results have shown that albuminuria correlates with the risk of adverse outcomes independently of eGFR [21]. Thus, the revised classification proposed by KDIGO in 2012 recommended a two-dimensional staging of CKD according to the urine ACR. In the present study, a general trend of higher prevalence of hyperuricemia or anemia through increased ACR levels was detected when the G3b patients were compared with the G3a patients. However, the prevalence of CKD-related complications was not found to be much higher in the macro-albuminuria group than that in the non-albuminuria group. Consistently, higher ACR was not significantly associated with a higher prevalence of CKD-related complications within the CKD G3a or CKD G3b group. The explanation for this observation might be that macro-albuminuria with fewer signs or symptoms did not have an influence on CKD-related complications in patients in the early stage of CKD. A cohort study is ongoing to reveal the association among ACR and CKD-related complications in Chinese patients with CKD.

Functioning in everyday activities and well-being are essential when considering chronic disease heath care. Previous studies found that patients with CKD undergo a barrage of symptoms and significant impairments in the HRQoL [22]. All HRQoL dimensions declined significantly with CKD stage, with the lowest scores in CKD 5 compared with healthy controls. Besides, the impaired HRQoL has been demonstrated to predict mortality and cardiovascular events [23, 24]. While HRQoL and increased mortality in patients with ESRD has been well-studied, less is understood about the link between the early stage of CKD and HRQoL in China.

These findings suggested that Chinese patients with CKD3 experience an overall burden of symptoms, impaired physical well-being, and low HRQoL. Patients with CKD G3b had lower scores on all HRQoL dimensions compared with patients with CKD G3a although the differences were small (1 or 2 points) between the two groups. Similar to the findings of the present study, other studies have shown that the differences in scores were quite small but still significant in patients with the early stage of CKD, indicating that KDQoL subscales were sensitive to differences in the CKD stage [14, 25]. More importantly, the change in KDQoL score predicted continued survival, hospitalization, and dialysis-attendance compliance in hemodialysis patients. Each 5-point increase in PCS scores was related to a 10% increase in survival and 6% fewer length of stay in the hospital. Each 5-point improvement in the MCS score was linked to 2% fewer hospital days [26]. After controlling for several variables, the CKD stage (G3b vs G3a) was only significantly associated with PCS. The results of the present study confirmed findings from other studies which found that eGFR values around 45 mL/(min 1.73 m2) are the threshold for the decrease in the HRQoL, especially in PCS [27].

The present study included the following limitations. Only relationship between variables, and not causal relationships, could be surmised due to the cross-sectional study design. Thus, longitudinal studies that consider qualitative evaluations ought to be conducted to seek a deeper understanding of the clinical difference in the prognosis of patients with CKD3 in China. When interpreting the results, it should be considered that the SF-12 used in the present study did not cover all measures in the HRQoL for patients with CKD, such as sleep, sexual and cognitive functioning.


In the present study, modest differences existed in many important clinical features and KDQoL between patients with G3a and G3b CKD in a Chinese population. Also, a significant association between CKD3 subdivision of the disease and PCS was detected. Although further work is needed, we can speculate based on these results the CKD3 subdivision may be clinically meaningful for Chinese patients with CKD.



Albumin-to-creatinine ratio


Chronic kidney disease


Chronic kidney disease epidemiology collaboration equation


CKD-mineral and bone disorders


Chinese cohort study of chronic kidney disease


Cardiovascular disease


Diabetes mellitus


Estimated glomerular filtration rate


end-stage renal disease


High blood pressure


High-density lipoprotein


health-related quality of life


High-sensitivity C-reactive protein


Intact parathyroid hormone


Interquartile range


Kidney disease outcomes quality initiative


Kidney disease quality of life


Low-density lipoprotein


Left ventricular end-systolic diameter


Mental summary scores


Physical summary scores


Standard deviations; UA, uric acid



The authors would like to express gratitude to every member of the C-STRIDE group for their close collaboration. Information on the contributions of the members of the C-STRIDE group can be found in the published literature [11].


This study was funded by grants from the National Key Technology R & D Program of the Ministry of Science and Technology (No.2011BAI10B01) and Chinese Society of Nephrology (No.15020090597).

Authors’ contributions

Conception or design of the work: QLZ, LXZ, MHZ; Data collection: ZZP, QJY, AX, YZ, YYX, WW, LH; Data analysis and interpretation: JWW, ZZP, QJY, HX; Drafting of the manuscript: ZZP, JWW; Statistical analysis: JWW, ZZP; Critical revision of the manuscript for important content: XXC, LJT, LXZ, MHZ; Person in charge of study: QLZ. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the ethics committee of Peking University First Hospital and Central South University Xiangya Hospital, China, and was in adherence with the Declaration of Helsinki. All subjects signed informed consent forms before data collection.

Consent for publication

Not applicable.

Competing interests

The authors declare that they do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, 410008, China
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, 100034, China
Institute of Nephrology, Peking University, Beijing, 100034, China
Key Laboratory of Renal Disease, National Health and Family Planning Commission of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, 100034, China


  1. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23(12):1917–28.View ArticlePubMedGoogle Scholar
  2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.View ArticlePubMedGoogle Scholar
  3. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.View ArticlePubMedGoogle Scholar
  4. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013;24(9):1478–83.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Hu JR, Coresh J. The public health dimension of chronic kidney disease: what we have learnt over the past decade. Nephrol Dial Transplant. 2017;32(suppl_2):ii113–20.View ArticlePubMedGoogle Scholar
  6. Zhang L, Wang H. Chronic kidney disease epidemic: cost and health care implications in China. Semin Nephrol. 2009;29(5):483–6.View ArticlePubMedGoogle Scholar
  7. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.View ArticlePubMedGoogle Scholar
  8. Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, Li Y, Yeung RO, Wang J, Matsushita K, et al. Trends in Chronic Kidney Disease in China. N Engl J Med. 2016;375(9):905–6.View ArticlePubMedGoogle Scholar
  9. Cao X, Zhou J, Yuan H, Wu L, Chen Z. Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort. BMC Nephrol. 2015;16:85.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Yuan J, Zou XR, Han SP, Cheng H, Wang L, Wang JW, Zhang LX, Zhao MH, Wang XQ, group CSs. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2017;18(1):23.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Gao B, Zhang L, Wang H, Zhao M. Chinese cohort study of chronic kidney disease: design and methods. Chin Med J. 2014;127(11):2180–5.PubMedGoogle Scholar
  12. Chow SK, Tam BM. Is the kidney disease quality of life-36 (KDQOL-36) a valid instrument for Chinese dialysis patients? BMC Nephrol. 2014;15:199.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Tao X, Chow SK, Wong FK. Determining the validity and reliability of the Chinese version of the Kidney Disease Quality of Life Questionnaire (KDQOL-36). BMC Nephrol. 2014;15:115.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, Go AS, Chertow GM. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801–8.View ArticlePubMedGoogle Scholar
  15. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol. 2002;22(6):449–58.View ArticlePubMedGoogle Scholar
  16. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.View ArticlePubMedGoogle Scholar
  17. Hallan SI, Orth SR. The conundrum of chronic kidney disease classification and end-stage renal risk prediction in the elderly--what is the right approach? Nephron Clin Pract. 2010;116(4):c307–16.View ArticlePubMedGoogle Scholar
  18. Abutaleb N. Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components. Nephrol Dial Transplant. 2007;22(9):2728–9.View ArticlePubMedGoogle Scholar
  19. Ito H, Oshikiri K, Mifune M, Abe M, Antoku S, Takeuchi Y, Togane M, Yukawa C. The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. J Diabetes Complicat. 2012;26(4):286–90.View ArticlePubMedGoogle Scholar
  20. Zhang JJ, Yu GZ, Zheng ZH, Liu YF, Du YY, Quan SX, Liu YJ, Lv JC, Zhang H. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy. PLoS One. 2017;12(4):e0175828.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20(5):1069–77.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057–64.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Lowrie EG, Curtin RB, LePain N, Schatell D. Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis. 2003;41(6):1286–92.View ArticlePubMedGoogle Scholar
  24. Rayner HC, Zepel L, Fuller DS, Morgenstern H, Karaboyas A, Culleton BF, Mapes DL, Lopes AA, Gillespie BW, Hasegawa T, et al. Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2014;64(1):86–94.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014;63(2):214–26.View ArticlePubMedGoogle Scholar
  26. DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis. 1997;30(2):204–12.View ArticlePubMedGoogle Scholar
  27. Chin HJ, Song YR, Lee JJ, Lee SB, Kim KW, Na KY, Kim S, Chae DW. Moderately decreased renal function negatively affects the health-related quality of life among the elderly Korean population: a population-based study. Nephrol Dial Transplant. 2008;23(9):2810–7.View ArticlePubMedGoogle Scholar


© The Author(s). 2017